donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > HAE Haemonetics > Key Indicators
HAE Haemonetics
68.650
-0.930-1.34%
Post Mkt Price
68.65000.00%
YOY
Do not show
Hide blank lines
(FY)2022/04/02(Q4)2022/04/02(Q3)2022/01/01(Q2)2021/10/02
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
-3.53% 242.4395 -3.53% 242.4395 -- 243.6007 4.82% 249.6879
Receivable Turnover(T)
16.42% 6.9229 16.42% 6.9229 -- 6.3144 16.36% 6.6033
Inventory Turnover(T)
-0.62% 1.5843 -0.62% 1.5843 -- 1.659 -5.67% 1.5963
Fixed Assets Turnover(T)
12.88% 4.1727 12.88% 4.1727 -- 3.9813 12.49% 4.0238
Total Asset Rate(T)
-4.28% 0.5398 -4.28% 0.5398 -- 0.6053 -16.17% 0.5801
ROIC
-49.9% 3.622% -49.9% 3.622% -- 2.902% -70.03% 3.414%
ROE
-51.4% 5.857% -51.4% 5.857% -- 3.116% -73.04% 4.573%
ROA
-54.21% 2.358% -54.21% 2.358% -- 1.435% -76.15% 1.941%
FCF to Sales
-7.49% 7.627% -7.49% 7.627% -- 3.434% -56.45% 5.770%
FCF to Net Income
93.4% 174.649% 93.4% 174.649% -- 144.886% 53.08% 172.461%
Efficiency Ratios
ROE 5 Year Average
27.39% 8.792% -- -- -- -- -- --
ROA 5 Year Average
25.68% 4.318% -- -- -- -- -- --
Average 5 Years ROIC
25.36% 6.129% -- -- -- -- -- --
Profitability Ratios TTM
Gross Margin
11.36% 50.897% 11.36% 50.897% -- 47.313% -4.39% 46.335%
Operating Margin
8.45% 7.222% 8.45% 7.222% -- 3.315% -70.85% 3.776%
Net Margin
-52.16% 4.367% -52.16% 4.367% -- 2.370% -71.55% 3.346%
EBITDA Margin
-10.11% 0.1797% -10.11% 0.1797% -- 0.1419% -43.86% 0.1461%
R & D Expense Ratio
24.93% 4.710% 24.93% 4.710% -- 4.660% 32.84% 4.490%
Sales Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Administration Expense Rate
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Financial Health Ratios
Long-Term Debt to Equity Ratio
-27.52% 74.650% -27.52% 74.650% -- 86.637% 124.71% 99.928%
Total Assets to Common Equity
-0.23% 248.155% -0.23% 248.155% -- 250.607% 21.46% 257.891%
Debt to Asset Ratio
-2.05% 104.185% -2.05% 104.185% -- 106.350% 60.89% 111.771%
Current Ratio
-37.52% 1.7094 -37.52% 1.7094 -- 2.0524 7.94% 2.424
Quick Ratio
-24.94% 0.9471 -24.94% 0.9471 -- 1.1025 -6.9% 1.1569
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
170.02% 0.875% -- -- -- -- -- --
Revenue CAGR(5Y)
368.66% 2.308% -- -- -- -- -- --
Net Income CAGR(3Y)
-137.42% -7.620% -- -- -- -- -- --
FCF 1 Year Growth
116.14% 5.558% -- -- -- -- -- --
FCF CAGR(3Y)
211.41% 23.394% -- -- -- -- -- --
FCF CAGR(5Y)
-106.55% -1.953% -- -- -- -- -- --
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital’s blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient’s overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
CEO: Simon, Christopher A.
Market: NYSE
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...